These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

75 related items for PubMed ID: 3237566

  • 1. The effect of buthobendin on glycolysis in rabbit myocardial slices in vitro.
    Marchut E, Gumińska M, Kedryna T.
    Pol J Pharmacol Pharm; 1988; 40(2):167-72. PubMed ID: 3237566
    [Abstract] [Full Text] [Related]

  • 2. The effect of a new antiarrhythmic drug: Craviten (M-71) on the ATP level in heart muscle slices in vitro.
    Gumińska M, Kedryna T, Marchut E, Eckstein M.
    Pol J Pharmacol Pharm; 1980; 32(6):877-82. PubMed ID: 7243683
    [Abstract] [Full Text] [Related]

  • 3. The effect of Craviten, a new antiarrhythmic drug, its 2R, 2'R isomer, quinidine and procaine amide on human platelet aggregation.
    Kedryna T, Gumińska M, Eckstein M.
    Pol J Pharmacol Pharm; 1980; 32(6):883-8. PubMed ID: 7243684
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Metabolic effects of bunaftine, a new antiarrhythmic agent: comparison with quinidine, ajmaline, procainamide, xylocaine and propranolol.
    Castellucci A.
    Arzneimittelforschung; 1976 Feb; 26(2):241-4. PubMed ID: 947206
    [Abstract] [Full Text] [Related]

  • 6. The effect of buthobendin on human erythrocyte membrane ATPases.
    Grabowska M, Gumińska M.
    Pol J Pharmacol Pharm; 1987 Feb; 39(4):371-7. PubMed ID: 2966930
    [Abstract] [Full Text] [Related]

  • 7. Pharmacological properties of Craviten (M-71).
    Maj J, Kulig D, Myśliwiec D, Bugielska Z, Tomsa E, Zaczyńska-Kostrakiewicz M.
    Pol J Pharmacol Pharm; 1980 Feb; 32(6):855-75. PubMed ID: 7243682
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. In vitro study of (2S, 2'S) N,N'-dimethyl-N, N'-bis [1(3', 4', 5'-trimethoxybenzoyloxy) butyl-2] ethylenediamine salts and their bioavailability.
    Krówczyński L, Kluczykowska B, Stozek T, Wajdowicz A, Bartkowicz S.
    Pol J Pharmacol Pharm; 1980 Feb; 32(6):909-15. PubMed ID: 7243687
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. [Antiarrhythmic, cardiovascular and toxic actions of N,N'-bis-[3-(2'-ethoxyphenoxy)-2-hydroxypropyl]-ethlenediamine (Falirytmin) as compared to propranolol, quinidine and ajmaline].
    Terhaag B, Förster W.
    Pharmazie; 1976 Feb; 31(9):635-9. PubMed ID: 1019213
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Aerobic vs anaerobic metabolism during ischemia in heart muscle.
    Das DK, Engelman RM, Rousou JA, Breyer RH.
    Ann Chir Gynaecol; 1987 Feb; 76(1):68-76. PubMed ID: 3592561
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Effect of butobendin on dopamine beta-hydroxylase in vitro.
    Grabowska M, Gumińska M.
    Pol J Pharmacol; 1996 Feb; 48(1):39-45. PubMed ID: 9112626
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 4.